GRTXD · Galera Therapeutics, Inc.
$18.99
At close · Aug 3
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result of these conditions, it expects its existing cash and cash equivalents as of March 31, 2026 will not enable the Company to fund its operating expenses and capital expenditure requirements for more than one year after the date these consolidated financial statements are issued, and therefore management has concluded that substantial doubt exists about the Company's ability to continue as a going concern.”View the 10-Q filed May 14, 2026
Market Cap
$3.05B
Shares
160.43M
Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Past events
| Date | Event | Type |
|---|---|---|
| 2023-09-11 | Galera at H.C. Wainwright 25th Annual Global Investment Conference | Conference |
| 2023-08-10 | Galera Therapeutics Conference Call | Conference |
| 2022-11-29 | Galera at Piper Sandler Annual Healthcare Conference | Conference |
| 2022-09-12 | Galera at H.C. Wainwright 24th Annual Global Investment Conference | Conference |
| 2022-06-09 | Galera at Jefferies Healthcare Conference | Conference |
| 2022-01-10 | Galera at H.C. Wainwright BioConnect Conference | Conference |
| 2021-12-14 | Galera ROMAN Phase 3 Trial Update | Event |
| 2021-11-18 | Galera at Jefferies London Healthcare Conference | Conference |
| 2021-09-29 | Cantor Fitzgerald Global Healthcare Conference | Conference |
| 2021-09-23 | Galera Virtual KOL Event: Radiotherapy-Induced Severe Oral Mucositis in Patients with Head and Neck Cancer | Event |